All
A Lower Dose of Xpovio May Help Patients With Myeloma Get the ‘Full Benefit of the Drug’
January 13th 2022Although patients with multiple myeloma may be concerned that a reduction in treatment dose may be less effective, an expert from The Tisch Cancer Institute stresses that it may be more beneficial.
‘Shock to the Heart’: A Cancer Survivor Recalls the Emotions of Her First Chemo Treatment
January 12th 2022After not knowing quite what to expect from her first chemotherapy treatment, colorectal cancer survivor Yla Flores describes the pain she felt in her heart after seeing other patients in worse conditions.
Cancer Survivors Share the Unexpected Side Effects Experienced During and After Treatment
January 11th 2022From mouth sores to cold sensitivities as well as a continued taste of chemicals, cancer survivors recently shared some of the more unexpected side effects they experienced during and after treatment.
Trial Launched to Assess Safety and Efficacy of Novel Drug in Rare Type of Head and Neck Cancer
January 10th 2022A phase 2 trial was recently launched to examine the safety and efficacy of oral inhibitor VK-2019 in patients with advanced Epstein-Barr Virus-positive nasopharyngeal carcinoma, a rare type of head and neck cancer, and lymphoma.
Increased Fiber Intake May Improve Immunotherapy Responses in Patients With Skin Cancer Subtype
January 10th 2022Patients with melanoma who consumed a high-fiber diet may have a better response to immunotherapy, although the benefit was not as great if the fiber was obtained via probiotic supplements.
Calquence Linked to Fewer Heart-Related, Other Toxicities in Patients With CLL Than Imbruvica
January 7th 2022Treatment with Calquence resulted in fewer toxicities, including atrial fibrillation, flutter and hypertension, in patients with previously treated chronic lymphocytic leukemia, compared with Imbruvica treatment, according to findings from the analysis of a phase 3 trial.
Expert Explores the Relationship Between Down Syndrome and Leukemia
January 6th 2022In this episode of the “Cancer Horizons” podcast, an expert unpacks cancer risks for individuals with Down syndrome and analyzes the results of a recent study about mortality risks for childhood survivors later in life.
Keytruda/Chemo Combo Is ‘Great News’ for Patients With TNBC, ‘But We Need Much More’
January 6th 2022An expert discusses improvements in survival outcomes for patients with triple-negative breast cancer who received Keytruda plus chemotherapy — now considered the standard of care — but urges that more researched is always needed for this patient population.
Trial Underway to Assess Efficacy of Novel Radiopharmaceutical Drug in Neuroendocrine Tumors
January 5th 2022The phase 3 COMPOSE trial will look at the efficacy of using 177lu-edotreotide — a novel radiopharmaceutical that is designed to limit radiation exposure to normal tissue — in patients with later stage neuroendocrine tumors.